RxDoctor Payments Data

Charles Sims, MD

Internal Medicine · Asheville, NCNPI 1689010050

Payments from drug & device makers

$8,376in general payments, 2019–2025

Across 527 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$891
  • Novo Nordisk$848
  • Pfizer$771
  • Viiv Healthcare Company$728
  • AbbVie$697
  • Amgen$604
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,376 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$285,361
Medicare patients
451
Services billed
8,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$126,596
JardianceEmpagliflozin107$98,465
XareltoRivaroxaban118$95,113
OzempicSemaglutide80$87,707
MounjaroTirzepatide30$42,826
JanuviaSitagliptin Phosphate46$41,970
ProliaDenosumab24$41,716
Repatha SureclickEvolocumab17$23,962
UbrelvyUbrogepant21$23,019
WegovySemaglutide16$21,912
SymbicortBudesonide/Formoterol Fumarate56$19,364
FarxigaDapagliflozin Propanediol30$17,367
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,949
InvokanaCanagliflozin11$14,902
MyrbetriqMirabegron26$12,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$771$126,596138 claims
Johnson & JohnsonXarelto, Invokana$385$110,015129 claims
Novo NordiskOzempic, Wegovy$848$109,61996 claims
Boehringer IngelheimJardiance$217$98,465107 claims
Lilly USA, LLCMounjaro$891$42,82630 claims
MerckJanuvia$89$41,97046 claims
AmgenProlia$604$41,71624 claims
AstraZenecaSymbicort, Farxiga$260$36,73186 claims
AbbVieUbrelvy, Synthroid$697$31,502127 claims
GSKTrelegy Ellipta$567$16,94920 claims
Astellas Pharma US IncMyrbetriq$167$12,72026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →